Jolles, Stephen http://orcid.org/0000-0002-7394-6804
Rojavin, Mikhail A.
Lawo, John-Philip
Nelson, Robert Jr
Wasserman, Richard L.
Borte, Michael
Tortorici, Michael A.
Imai, Kohsuke
Kanegane, Hirokazu
Funding for this research was provided by:
CSL Behring
Article History
Received: 6 April 2018
Accepted: 4 October 2018
First Online: 10 November 2018
Compliance with Ethical Standards
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients prior to inclusion in the study.
: Stephen Jolles has participated in advisory boards, trials, projects, and has been a speaker with Baxalta, CSL Behring, Shire, Thermofisher, Swedish Orphan Biovitrum, Biotest, Binding Site, Grifols, BPL, Octapharma, LFB, GSK, Weatherden, Zarodex, Sanofi, and UCB Pharma. Mikhail Rojavin, John-Philip Lawo, and Michael A. Tortorici are employees of CSL Behring. Robert Nelson Jr. reported no conflicts of interest. Richard L. Wasserman has been Consultant and Investigator for BPL, Korean Green Cross, Prometic, Therapure, and Shire, and has been a speaker for Shire. Michael Borte has no potential conflicts of interest. Kohsuke Imai has been a Consultant for CSL Behring, a Speaker for CSL Behring, Novartis, The Japan Blood Products Organization. Hirokazu Kanegane has received research grant support from CSL Behring and the Japanese Blood Products Organization, and has been a Consultant for CSL Behring.